Efficacy of Definitive Radiotherapy for Base of Tongue Cancer Evaluated
the Cancer Therapy Advisor take:
According to a new study published in the American Journal of Clinical Oncology, the efficacy of definitive radiotherapy for the treatment of patients with base of the tongue cancer in a private practice setting is similar to that already published in the literature.
For the study, researchers sought to retrospectively investigate the efficacy of definitive radiotherapy alone or combined with chemotherapy for the treatment of patients with squamous cell carcinoma of the base of the tongue in a private practice.
Researchers identified 48 patients with squamous cell carcinoma of the base of the tongue who underwent definitive radiotherapy. All patients were followed for a median of 2.7 years, but living patients had a median follow-up of 4.9 years.
Two-thirds of patients received radiotherapy two times a day and the median overall duration of treatment was 45.5 days. Patients received a median total dose of 74.4 Gy. Comcomitant chemotherapy was given to 96% of patients and adjuvant chemotherapy was given to 58% of patients.
Results showed that at 5 years, those with T1 to T2 disease had a 91% local control rate, T3 had an 83% local control rate, and T4 had 12%. At 5 years, the overall survival rates for those with sate 1 to 2 disease were 67%, 56% for stage 3, 45% for stage 4A, and 33% for stage 4B.
Efficacy of definitive radiotherapy for the treatment of patients with base of the tongue cancer in a private practice evaluated.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Immunotherapy in Glioblastoma: Peaks and Pits
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed